Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Epizyme, Inc.
  6. News
  7. Summary
    EPZM   US29428V1044

EPIZYME, INC.

(EPZM)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Epizyme : to Participate in Jefferies Virtual Healthcare Conference

05/25/2021 | 06:31am EDT

Epizyme, (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies, today announced that Robert Bazemore, President and Chief Executive Officer, will participate in a fireside chat during the Jefferies Virtual Healthcare Conference on Tuesday, June 1, 2021 at 2:30 p.m. ET.

A live webcast of the fireside chat will be available in the investor section of the Company's website at www.epizyme.com, and will be archived for 60 days following the call.

About Epizyme, Inc.

Epizyme, Inc. is a fully integrated, commercial-stage biopharmaceutical company committed to its mission of rewriting treatment for cancer and other serious diseases through novel epigenetic medicines. In addition to an active research and discovery pipeline, Epizyme has one U.S. FDA approved product, TAZVERIK® (tazemetostat), for the treatment of adults and pediatric patients aged 16 years and older with metastatic or locally advanced epithelioid sarcoma (ES) who are not eligible for complete resection; adult patients with relapsed or refractory follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least two prior systemic therapies; and adult patients with relapsed or refractory follicular lymphoma who have no satisfactory alternative treatment options. These indications are approved under accelerated approval based on overall response rate and duration of response. Continued approval for these indications may be contingent upon verification and description of clinical benefit in confirmatory trials(s). The Company is also exploring the treatment potential of tazemetostat in investigational clinical trials in other solid tumors and hematological malignancies, as a monotherapy and combination therapy in both relapsed and front-line disease settings. By focusing on the genetic drivers of disease, Epizyme seeks to match medicines with the patients who need them. For more information, visit www.epizyme.com.

TAZVERIK® is a registered trademark of Epizyme, Inc.


© Business Wire 2021
All news about EPIZYME, INC.
06/29TURNING POINT THERAPEUTICS : Names New Chief Financial Officer
MT
06/28EPIZYME, INC. : Change in Directors or Principal Officers (form 8-K)
AQ
06/28Epizyme, Inc. Announces Resignation of Paolo Tombesi as the Chief Financial O..
CI
06/28Epizyme, Inc. Announces That Matthew E. Ros Will Serve as Principal Financial..
CI
06/25EPIZYME, INC.(NASDAQGS : EPZM) dropped from Russell 3000 Value Index
CI
06/25EPIZYME, INC.(NASDAQGS : EPZM) added to Russell 3000E Growth Index
CI
06/25EPIZYME, INC.(NASDAQGS : EPZM) added to Russell Microcap Growth Index
CI
06/25EPIZYME, INC.(NASDAQGS : EPZM) dropped from Russell 3000E Value Index
CI
06/25EPIZYME, INC.(NASDAQGS : EPZM) dropped from Russell 2500 Value Index
CI
06/25EPIZYME, INC.(NASDAQGS : EPZM) dropped from Russell Small Cap Comp Value Index
CI
More news
Financials (USD)
Sales 2021 44,1 M - -
Net income 2021 -250 M - -
Net cash 2021 62,2 M - -
P/E ratio 2021 -2,84x
Yield 2021 -
Capitalization 710 M 710 M -
EV / Sales 2021 14,7x
EV / Sales 2022 5,66x
Nbr of Employees 304
Free-Float 77,5%
Chart EPIZYME, INC.
Duration : Period :
Epizyme, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends EPIZYME, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 8
Last Close Price 6,96 $
Average target price 18,63 $
Spread / Average Target 168%
EPS Revisions
Managers and Directors
Robert B. Bazemore President, Chief Executive Officer & Director
Paolo Tombesi Chief Financial Officer
David M. Mott Chairman
Shefali Agarwal Executive VP, Chief Medical & Development Officer
Jeffery L. Kutok Chief Scientific Officer & Executive VP
Sector and Competitors
1st jan.Capi. (M$)
EPIZYME, INC.-35.91%990
GILEAD SCIENCES, INC.18.47%85 134
WUXI APPTEC CO., LTD.37.17%71 226
REGENERON PHARMACEUTICALS21.37%57 013
BIONTECH SE245.88%55 555
VERTEX PHARMACEUTICALS-15.16%50 308